2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 142 filers reported holding 2SEVENTY BIO INC in Q1 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $225,004 | -61.3% | 57,399 | 0.0% | 0.00% | – |
| Q2 2023 | $580,878 | +61.9% | 57,399 | +63.2% | 0.00% | – |
| Q1 2023 | $358,785 | +8.0% | 35,175 | -0.8% | 0.00% | – |
| Q4 2022 | $332,082 | -35.6% | 35,441 | 0.0% | 0.00% | – |
| Q3 2022 | $516,000 | +24.3% | 35,441 | +12.7% | 0.00% | – |
| Q2 2022 | $415,000 | +2.2% | 31,441 | +32.2% | 0.00% | – |
| Q1 2022 | $406,000 | -43.6% | 23,775 | -15.3% | 0.00% | – |
| Q4 2021 | $720,000 | – | 28,075 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,890,706 | $49,493,945 | 6.81% |
| CHI Advisors LLC | 852,007 | $8,622,311 | 2.62% |
| Casdin Capital, LLC | 2,023,913 | $20,482,000 | 1.79% |
| Newtyn Management, LLC | 737,744 | $7,465,969 | 1.76% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,258,078 | 1.47% |
| DAFNA Capital Management LLC | 496,416 | $5,023,730 | 1.37% |
| AlphaCentric Advisors LLC | 180,000 | $1,821,600 | 1.01% |
| SECTORAL ASSET MANAGEMENT INC | 462,485 | $4,680,348 | 0.78% |
| CLOUGH CAPITAL PARTNERS L P | 529,110 | $5,354,593 | 0.54% |
| Bleichroeder LP | 255,230 | $2,582,928 | 0.52% |